Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.077 AUD | +2.67% | +1.33% | +10.14% |
04-17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
04-17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+10.14% | 49.71M | |
-7.63% | 3.08B | |
-5.53% | 172M | |
-14.03% | 85.92M | |
-45.91% | 51.5M |
- Stock Market
- Equities
- NTI Stock
- News Neurotech International Limited
- Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism